The Impact of Moderate-to-Severe Atopic Dermatitis on Sleep in Adolescent Patients from the Adelphi Real World Disease Specific Programme (DSP)TM

Main Article Content

Dr Amy Paller
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Dr Vimal H. Prajapati
University of Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Probity Medical Research, Calgary, Alberta, Canada;

Dr Mercedes E. Gonzalez
Pediatric Skin Research, Miami, Florida, USA

Dr Evangeline Pierce
Eli Lilly and Company, Indianapolis, Indiana, USA

Dr Zach Dawson
Eli Lilly and Company, Indianapolis, Indiana, USA

Dr Eric Wolf
Eli Lilly and Company, Indianapolis, Indiana, USA

Ms. Niamh Harvey
Adelphi Real World, Cheshire, UK

Mr. Oliver Howell
Adelphi Real World, Cheshire, UK

Mr. David Bell
Adelphi Real World, Cheshire, UK

Dr Lawrence F. Eichenfield
University of California San Diego School of Medicine, California, USA

Keywords

atopic dermatiits, adolescents, sleep

References

1. Huang A, et al. Curr Treat Options Allergy. 2017;4(3):355-369.

2. Anderson P, et al. Curr Med Res Opin. 2008;24:3063–72.

3. Anderson P, et al. Curr Med Res Opin. 2023;39(12):1701–15.

4. Babineaux SM, et al. BMJ Open. 2016;6(8):e010352.

5. Higgins V, et al. Diabetes Metab Syndr Obes. 2016;9:371–80.

6. Monk E. SocArXiv. 2023. doi:10.31235/osf.io/pdf4c.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/vmn4mf70

Article Details

How to Cite
1.
The Impact of Moderate-to-Severe Atopic Dermatitis on Sleep in Adolescent Patients from the Adelphi Real World Disease Specific Programme (DSP)TM. J of Skin. 2025;9(6):s608. doi:10.25251/vmn4mf70
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Poster Presentations from FC25 Dermatology Conference®: Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>